Search

Search Constraints

You searched for: Author/Creator Vernieri, Claudio

Search Results

1. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II–III HER2-negative breast cancer: a 10-year, retrospective analysis. (December 2020)

3. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. (March 2017)

4. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. (September 2022)

5. Hormone receptor status influences the impact of body mass index and hyperglycemia on the risk of tumor relapse in early-stage HER2-positive breast cancer patients. (April 2021)

6. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine‐Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. (3rd January 2019)

7. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). Issue 7 (7th January 2019)

8. Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer. Issue 2 (21st August 2018)

9. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. Issue 3 (27th May 2020)

10. LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. Issue 3 (27th May 2020)